Report
Grifols B : Q1 EBITDA beats our numbers. FY 2023 guidance nuanced slightly upwards
>Plasma collection keeps growing at a double-digit pace - Q1 group sales grew by 23% (+18% cc vs +21% in Q4 2022) reaching € 1.6bn, a touch ahead of our numbers and the consensus. Biopharma posted a robust +26% y-o-y growth (+15% l-f-l , +21% cc) to € 1.3bn driven by: i/ a still solid plasma collection growth (+11% in Q1 vs +25% in FY 2022) helped by the US southern border re-opening, ii/ robust IGg demand and price upticks, iii/ growing demand, higher prices and fav...
Underlying
Grifols S.A. Pref Class B
Provider
Oddo BHF
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Juan Ros-Padilla
Other Reports on these Companies
Other Reports from Oddo BHF
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.